רווחיות מכירות לפי רווח נקי Xenetic Biosciences, Inc. (XBIO)

Xenetic Biosciences (XBIO) automates the creation of oncology drugs through robotic small-molecule screening. The net profit margin illustrates management efficiency, where the -123.70 mark reflects the latest data. The asset remains independent of macroeconomic trends, as demand for treatment is constant. Currently, Xenetic Biosciences is focusing on R&D, developing the XCART platform for B-cell lymphoma therapy.
xeneticbio.com (XBIO) - פילוחי מדדים ודוחות פיננסיים

A defensive portfolio requires rigorous screening of an asset's ability to generate a net residual from every dollar of revenue. This metric measures the share of final profit within total turnover, determining the business's actual margin of safety. For Xenetic Biosciences (XBIO), at the preclinical research stage of DNase, this metric reflects the efficiency of R&D cost management. The trend in net turnover profitability allows for an assessment of the company's financial stability within the laboratory cycle.